. Author manuscript; available in PMC: 2019 Oct 30.

Published in final edited form as: Clin Cancer Res. 2019 Jul 15;25(19):5752–5758. doi: 10.1158/1078-0432.CCR-18-3453

Table 3.

Molecular Analysis of Tumor Specimens and Tumor Measurements

Patient	HPV Status	pErbB3^a (RF/mm2)			Ki67^b			NRG1^c	NRG2^c	ErbB3^c	PTEN^c	Tumor Measurement (% Change)^d
		Pre	Post	% Change	Pre	Post	% Change
112–02	−	0.45	BLQ	−69%	4820	6450	34%	++	−	+	+	−26
102–02	+	0.54	0.46	−15%	5266	264	−95%	++	++	++++	+	−16
108–02	+	0.60	BLQ	−77%	2525	1858	−26%	+	−	+	Loss	−6
101–02	−	0.73	0.39	−47%	198	446	125%	+++	−	+	+	−5
111–02	−	0.74	BLQ	−81%	5035	4187	−17%	+	−	+++	Loss	−4
104–02	−	0.42	0.21	−51%	2931	3332	14%	−	+	+	+	0
107–01	−	1.02	0.64	−37%	6024	3197	−47%	+	−	++	+	0
110–01	−	1.03	BLQ	−86%	6422	541	−92%	+	−	+	+	0
103–02	−	0.59	0.73	22%	531	1064	100%	+	−	+	+	11
105–01	−	0.41	0.41	0%	6200	8881	43%	+	−	++++	+	13
113–02	−	0.70	0.35	−50%	751	6396	752%	++	−	−	+	17
109–02	+	1.04	0.48	−54%	6629	7160	8%	+	−	+++	+	26

^a.

ErbB3 phosphorylation (pErbB3) determined using quantitative VeraTag® of pre- and post-treatment biopsies for all patients except 108–02 (post-treatment results determined using resection sample). Data represent change from pre- to post-treatment samples.

^b.

Ki67 expression assessed by IHC (AQUA®) in pre- and post-treatment samples.

^c.

NRG1, NRG2, ErbB3, and PTEN assessed using post-treatment tumor resection samples for all patients except 102–02, 103–02, and 104–02 (pre-treatment biopsies were evaluated). mRNA expression levels of NRG1, NRG2, ErbB3 evaluated by quantitative RNAScope® assays (−, not different from the negative control probe; +, expression level of 1.2 – 2.5; ++, expression level of 2.6–3.8; +++, expression level of 3.9–5.2; ++++, expression level >5.2). PTEN expression assessed by IHC (AQUA®).

^d.

Percent change from pre- to post-treatment in the sum of the longest diameters of RECIST 1.1 target lesions. BLQ, below the limit of quantification